ClinicalTrials.gg
CompletedNCT05089019Updated Mar 17, 2025Results posted

A Study Comparing Two Formulations of Selpercatinib (LY3527723) in Healthy Participants

A Phase 1 interventional study of Selpercatinib in Healthy, sponsored by Loxo Oncology, Inc.. Completed at 4 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-17.

Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
224
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as different formulations. The information about any adverse effects experienced will be collected and the tolerability of selpercatinib will also be evaluated. The study may last up to 56 days including the 28 days of screening period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Loxo Oncology, Inc. is the lead sponsor of 17 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

First submitted after Loxo Oncology, Inc. became part of Eli Lilly and Company.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, and vital signs.
  • Participants who have clinical laboratory test results within the normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not by the investigator.

Exclusion criteria

Exclusion Criteria:

  • Have a history of allergic reactions to medications or food products
  • Have a abnormality of blood pressure and/or pulse rate as determined by the investigator
  • Clinically significant abnormalities on as determined by the investigator or prolongation of the or QTcF >450 msec at screening
  • Have clinically significant active cardiovascular disease or history of myocardial infarction within 6 months prior to the planned start of selpercatinib
  • Have a history or presence of cardiovascular, respiratory, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the product; or of interfering with the interpretation of data. Appendectomy, splenectomy, and cholecystectomy are considered as acceptable
  • Use of H2 blockers, proton pump inhibitors, and other drugs that affect selpercatinib exposure within 7 days of screening
  • Are intending to use over-the-counter or prescription medication, including dietary supplements, within 14 days prior to dosing and until study discharge (apart from occasional acetaminophen (≤2 g/24 hours), hormonal , or hormone replacement therapy)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
224 participants (actual)

Study arms

  • Experimental
    Selpercatinib (Test)

    160 mg Selpercatinib (tablet formulation) given orally on days 1 and 15.

    Drug: Selpercatinib

  • Active comparator
    Selpercatinib (Reference)

    160 mg Selpercatinib (2 X 80 mg capsule formulation) given orally on days 1 and 15.

    Drug: Selpercatinib

Interventions

  • Administered orally

    Also known as: LY3527723, LOXO-292

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib

    PK: Cmax of Selpercatinib

    Time frame: Day 1 and Day 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 192, 240, and 312 hours (h) postdose;

  2. PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib

    PK: AUC\[0-∞\] of Selpercatinib.

    Time frame: Day 1 and Day 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 192, 240, and 312 hours (h) postdose;

  3. Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib

    PK: AUC\[0-tlast\] of Selpercatinib

    Time frame: Day 1 and Day 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 192, 240, and 312 hours (h) postdose;

07

Results

Posted Mar 17, 2025

Participant flow

Period 1
Participant flow — Period 1
MilestoneSequence 1 - Selpercatinib Reference/TestSequence 2 - Selpercatinib Test/Reference
Started112112
Received at least one dose of study drug112112
Completed112111
Not completed01
Withdrew: Withdrawal by subject01
Washout Period
Participant flow — Washout Period
MilestoneSequence 1 - Selpercatinib Reference/TestSequence 2 - Selpercatinib Test/Reference
Started112111
Completed100104
Not completed127
Withdrew: Adverse event34
Withdrew: Lost to follow-up10
Withdrew: Physician decision20
Withdrew: Withdrawal by subject63
Period 2
Participant flow — Period 2
MilestoneSequence 1 - Selpercatinib Reference/TestSequence 2 - Selpercatinib Test/Reference
Started100104
Received at least one dose of study drug100104
Completed95101
Not completed53
Withdrew: Adverse event42
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib

PK: Cmax of Selpercatinib

Time frame:
Day 1 and Day 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 192, 240, and 312 hours (h) postdose;
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib
nanograms per milliliter (ng/mL)160 mg Selpercatinib (Reference)160 mg Selpercatinib (Test)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Selpercatinib1520 ± 611350 ± 91
Statistical analysis
  • 160 mg Selpercatinib (Reference) vs 160 mg Selpercatinib (Test) · Mixed Models Analysis · Ratio of geometric ls mean: 0.889 · 94.12% CI 0.810 to 0.976Ratio of Geometric Least Square (LS) Mean
PrimaryPK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib

PK: AUC\[0-∞\] of Selpercatinib.

Time frame:
Day 1 and Day 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 192, 240, and 312 hours (h) postdose;
Reported as:
Geometric mean · nanograms*hour per milliliter (ng*hr/mL)
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib
nanograms*hour per milliliter (ng*hr/mL)160 mg Selpercatinib (Reference)160 mg Selpercatinib (Test)
PK: Area Under the Plasma Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Selpercatinib20700 ± 4519300 ± 51
Statistical analysis
  • 160 mg Selpercatinib (Reference) vs 160 mg Selpercatinib (Test) · Mixed Models Analysis · Ratio of geometric ls mean: 0.927 · 94.12% CI 0.882 to 0.975
PrimaryArea Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib

PK: AUC\[0-tlast\] of Selpercatinib

Time frame:
Day 1 and Day 15: Predose, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 192, 240, and 312 hours (h) postdose;
Reported as:
Geometric mean · ng*hr/mL
Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib
ng*hr/mL160 mg Selpercatinib (Reference)160 mg Selpercatinib (Testt)
Area Under the Plasma Concentration Versus Time Curve From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Selpercatinib20200 ± 4718100 ± 65
Statistical analysis
  • 160 mg Selpercatinib (Reference) vs 160 mg Selpercatinib (Testt) · Mixed Models Analysis · Ratio of geometric ls mean: 0.891 · 94.12% CI 0.834 to 0.951

Adverse events

Collected over Baseline up to 28 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
160 mg Selpercatinib (2 x 80 mg Reference)0/216 (0%)0/216 (0%)0/216 (0%)
160 mg Selpercatinib (1 x 160 mg Test)0/212 (0%)0/212 (0%)0/212 (0%)

Baseline characteristics

All enrolled participants.

Age, Continuous
Age, Continuous(years)Sequence 1 - Selpercatinib Reference/TestSequence 2: Selpercatinib Test/ReferenceTotal
Mean42.1 ± 12.342.8 ± 12.442.5 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1 - Selpercatinib Reference/TestSequence 2: Selpercatinib Test/ReferenceTotal
Female5353106
Male5959118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1 - Selpercatinib Reference/TestSequence 2: Selpercatinib Test/ReferenceTotal
Hispanic or Latino353671
Not Hispanic or Latino7776153
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1 - Selpercatinib Reference/TestSequence 2: Selpercatinib Test/ReferenceTotal
American Indian or Alaska Native011
Asian6410
Native Hawaiian or Other Pacific Islander101
Black or African American453782
White5967126
More than one race134
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Sequence 1 - Selpercatinib Reference/TestSequence 2: Selpercatinib Test/ReferenceTotal
United States112112224
08

Study locations

4 sites
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • LabCorp CRU, Inc.
    Daytona Beach, Florida 32117, United States
  • Covance Dallas
    Dallas, Texas 75247, United States
  • LabCorp CRU, Inc.
    Madison, Wisconsin 53704, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2021 to primary completion in Jul 2022, 8 months.

Results were first posted in Mar 2025, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2021
First posted
Oct 22, 2021
StartActual
Oct 29, 2021
Primary completionActual
Jul 19, 2022
CompletionActual
Jul 19, 2022
Results first posted
Mar 17, 2025
Last update
Mar 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05089019
Responsible party
Sponsor
First posted
Oct 22, 2021
Start date
Oct 29, 2021
Primary completion
Jul 19, 2022
Completion
Jul 19, 2022
Results posted
Mar 17, 2025
Last update
Mar 17, 2025

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selpercatinib

Start the discussion